Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report

Chronic myeloid leukemia (CML) is a myeloproliferative disorder diagnosed by demonstrating the Philadelphia chromosome (Ph) or the BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) are the standard of therapy. There are increasing reports of hepatitis B virus reactivation (HBVr) in patients on...

Full description

Saved in:
Bibliographic Details
Published inCase reports in oncology Vol. 14; no. 2; pp. 1004 - 1009
Main Authors Ali Hailan, Yousef Mohammed, Mudawi, Deena, Yassin, Mohamed A.
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 24.06.2021
Karger Publishers
Subjects
Antiretroviral drugs
Cancer
Case Report
Case reports
Chronic illnesses
chronic myeloid leukemia
Coronaviruses
COVID-19
FDA approval
Hepatitis
Hepatitis B
hepatitis b virus reactivation
imatinib
Infections
Inhibitor drugs
Kinases
Laboratories
Leukemia
Patients
Severe acute respiratory syndrome coronavirus 2
Targeted cancer therapy
Tuberculosis
tyrosine kinase inhibitor
Hepatitis B virus reactivation
Imatinib
Chronic myeloid leukemia
Tyrosine kinase inhibitor
Hepatitis B
Online AccessGet full text

Cover

More Information
Summary:Chronic myeloid leukemia (CML) is a myeloproliferative disorder diagnosed by demonstrating the Philadelphia chromosome (Ph) or the BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) are the standard of therapy. There are increasing reports of hepatitis B virus reactivation (HBVr) in patients on this treatment. We report a case of a 46-year-old male patient diagnosed to have CML in the chronic phase and resolved hepatitis B infection. He was treated with imatinib as upfront therapy for CML and with lamivudine as prophylaxis against HBVr. The patient tolerated both treatments well with no adverse effects. The aim is to address the deficiencies in the literature in regard to managing these patients, prevention, and follow-up.
ISSN:1662-6575
1662-6575
DOI:10.1159/000516747